Betamethasone dipropionate
Side effects
Options: Show MedDRA Preferred Terms
| Side effect | Data for drug | Placebo | Labels | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |||
| Infection | x | ||||||||||
| Contusion | x | x | x | ||||||||
| Cushing's syndrome | x | x | x | x | x | x | |||||
| Folliculitis | x | x | x | x | x | x | x | x | |||
| Glycosuria | x | x | x | x | x | x | |||||
| Hyperaesthesia | x | ||||||||||
| Hyperglycaemia | x | x | x | x | x | x | |||||
| Hypertension | x | ||||||||||
| Hypertrichosis | x | x | x | x | x | x | x | x | |||
| Miliaria | x | x | x | x | x | x | x | x | x | ||
| Paraesthesia | x | x | |||||||||
| Pruritus | x | x | x | x | x | x | x | x | x | ||
| Telangiectasia | x | x | x | x | x | ||||||
| Erythema | x | x | x | x | x | x | |||||
| Urticaria | x | ||||||||||
| Skin atrophy | x | x | x | x | x | x | x | x | x | ||
| Dry skin | x | x | x | ||||||||
| Skin striae | x | x | x | x | x | x | x | x | x | ||
| Allergic contact dermatitis | x | x | x | x | x | x | x | x | x | ||
| Leukoderma | x | x | x | x | x | x | x | x | x | ||
| Acneiform eruption | x | x | x | x | x | x | x | x | |||
| Rash erythematous | x | ||||||||||
| Rash follicular | x | x | x | ||||||||
| Dermatitis perioral | x | x | x | x | x | x | x | x | x | ||
| Papule | x | ||||||||||
| Atrophy | x | ||||||||||
| Secondary infection | x | x | x | x | x | x | x | x | x | ||
| Stinging | x | x | x | ||||||||
| Loss of skin markings | x | ||||||||||
| Tingling sensation | x | x | |||||||||
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Color scheme:
standard – alternative
| 100% | ||
| 75% | ||
| 50% | ||
| 10% | ||
| frequent (1% to 100%) | ||
| infrequent (0.1% to 1%) | ||
| rare (<0.1%) | ||
| postmarketing | ||
| 0% | ||
| no frequency information | ||
| not found on label |
